118
Participants
Start Date
November 8, 2023
Primary Completion Date
September 11, 2024
Study Completion Date
May 23, 2026
LBL-007
LBL-007 will be administered at a standard dose intravenously.
Tislelizumab
Tislelizumab will be administered at a standard dose intravenously.
Chemotherapy Doublet
"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City
National Taiwan University Hospital, Taipei
Ramathibodi Hospital Mahidol University, Bangkok
Phramongkutklao Hospital, Ratchathewi
National Cancer Center, Goyang-si
Siriraj Hospital, Bangkok
Taipei Veterans General Hospital, Taipei
Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University), Ongkharak
China Medical University Hospital, Taichung
Changhua Christian Hospital, Changhua
Chonnam National University Hwasun Hospital, HwasunGun
Peking Union Medical College Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing
The First Peoples Hospital of Changzhou, Changzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Nantong Tumor Hospital Branch North, Nantong
Anhui Provincial Hospital, Hefei
The First Affiliated Hospital of Anhui Medical University, Hefei
Shandong Cancer Hospital, Jinan
The Second Affiliated Hospital of Shandong First Medical University, Taian
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Fujian Medical University Union Hospital, Fuzhou
Fujian Cancer Hospital, Fuzhou
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang
Anyang Cancer Hospital, Anyang
Nanyang Central Hospital, Nanyang
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Sichuan Cancer Hospital and Institute, Chengdu
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu
Lanzhou University Second Hospital, Lanzhou
General Hospital of Ningxia Medical University, Yinchuan
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
The Catholic University of Korea, Seoul St Marys Hospital, Seoul
Lead Sponsor
BeiGene
INDUSTRY